Exelixis Announces Results From COMET-1 Phase 3 Pivotal Trial Of Cabozantinib In Men W/ Metastatic Castration-Resistant Prostate Cancer; DId Not Meet Primary Endpoint
September 01, 2014 at 18:50 PM EDT
The trial did not meet its primary endpoint of demonstrating a statistically significant increase in overall survival (OS) for ...